Groupe Francophone Des Myelodysplasies
Clinical trials sponsored by Groupe Francophone Des Myelodysplasies, explained in plain language.
-
New combo tackles relapsed blood cancers after transplant
Disease control OngoingThis study tests a combination of two drugs (venetoclax and azacitidine) plus donor immune cells in 55 adults with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that returned after a stem cell transplant. The goal is to find the best dose and see if the treatment…
Phase: PHASE1, PHASE2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New pill combo shows promise for rare blood cancer patients who Can't get transplant
Disease control OngoingThis study is testing a combination of two oral medications, Onureg and Venclyxto, in people with a high-risk form of myelodysplastic syndromes (a blood cancer) who cannot have a stem cell transplant. The goal is to find the safest and most effective dose of Onureg when used with…
Phase: PHASE1, PHASE2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug cocktail shows promise for rare leukemia
Disease control OngoingThis study tests a combination of two drugs, azacitidine and venetoclax, in people with a high-risk form of chronic myelomonocytic leukemia (CMML). The goal is to see if the combo can shrink or control the cancer better than current treatments. About 44 adults will take part, and…
Phase: PHASE2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Leukemia treatment showdown: which works best?
Knowledge-focused OngoingThis registry study follows 400 patients with a specific type of leukemia (non-high-risk APL) who are 70 or younger. It compares two standard treatments: ATRA plus chemotherapy versus ATRA plus arsenic trioxide. The goal is to see which approach leads to better long-term outcomes…
Sponsor: Groupe Francophone des Myelodysplasies • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC